Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Vismodegib in locally advanced basal cell carcinoma in Slovenia
Avtorji:ID Mesti, Tanja (Avtor)
ID Sever, Maša (Avtor)
ID Ocvirk, Janja (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (448,27 KB)
MD5: 66E91885F3EF84346935C832F834BC41
 
URL URL - Izvorni URL, za dostop obiščite https://www.karger.com/Article/Pdf/525612
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background: Vismodegib is a first-in-class inhibitor of the hedgehog pathway for treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC. Objectives: The purpose of this study is to report outcomes of patients with laBCC, with basal cell carcinoma nevus syndrome (Gorlin Goltz syndrome [G-G Syn]) treated with vismodegib in routine clinical practice in Slovenia in 8.3-year period. Methods: In this retrospective cohort study, we analyzed baseline characteristics, outcomes, and treatment-related adverse events from locally advanced BCC. The patients were divided into two cohorts: 39 laBCC or multiple BCC patients and 7 patients with G-G Syn who were treated with vismodegib from November 2012 till January 2021. Results: During 100-month period, 46 patients were diagnosed with laBCC (26), multiple BCC (13), and G-G Syn (7), all inappropriate for surgery or radiotherapy. Baseline characteristics: median age was 72.8 years in laBCC + multiple BCC cohort and 47.4 years in G-G Syn cohort. The objective response rate was 80% in laBCC + multiple BCC and 86% in G-G Syn cohort. Disease control rate (DCR) was 95% in laBCC + multiple BCC and 100% in G-G Syn cohort. Median duration of treatment was 9.9 months (range: 1.5-43.1) in laBCC and multiple BCC cohort and 19.5 months (range: 3.6-94.1) in G-G Syn cohort. Majority of treatment-emergent adverse events (TEAEs) in laBCC or multiple BCC cohort were grade 1 or 2 (96%), only 4% of AEs were grade 3. Majority of TEAEs in G-G Syn cohort were also grade 1 or 2 (87%), 13% of AEs were grade 3. No grade 4 or 5 vismodegib-related AEs were reported. Conclusion: Vismodegib has shown meaningful efficacy with DCR from 95% to 100% in patients with laBCC, multiple BCC, and G-G Syn in Slovenia. TEAEs were successfully alleviated with multidisciplinary approach and early supportive care.
Ključne besede:basal cell carcinoma, early supportive care, Gorlin Goltz syndrome, multidisciplinary approach
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.01.2022
Založnik:S. Karger
Leto izida:2022
Št. strani:str. 1-7
Številčenje:Vol. , no.
PID:20.500.12556/DiRROS-15459 Novo okno
UDK:616.5
ISSN pri članku:1018-8665
DOI:10.1159/000525612 Novo okno
COBISS.SI-ID:117583107 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:07.09.2022
Število ogledov:429
Število prenosov:203
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Dermatology
Skrajšan naslov:Dermatology
Založnik:S.Karger
ISSN:1018-8665
COBISS.SI-ID:748308 Novo okno

Gradivo je financirano iz projekta

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0321-2020
Naslov:Napovedni dejavniki poteka bolezni in odgovora na zdravljenje pri različnih vrst raka

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:07.09.2022

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:bazalnocelični rak, sindrom Gorlin Goltz, večdisciplinarni pristop


Nazaj